Markets
Inovio Pharmaceuticals Stock Tumbles 5% After Earnings — Most Of Its Wider Loss Was Non-Cash
Launch preparations increased expenses, while a completed offering added approximately $80.5 million to its funding.
INO
Inovio Pharmaceuticals (INO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
INOVIO Expects Cash To Fund Operations Into Late 2027 Without Counting VOCERYQ Sales
Launch preparations increased selling and administrative costs, while lower research spending helped reduce total operating expenses.
Markets
Inovio Stock Soars 13% After Offering Update Extends Its Expected Cash Horizon
Expected net proceeds of about $80.5 million would fund operations into late fourth quarter 2027, versus an earlier first-quarter horizon.
Earnings
INOVIO Expects About $80.5 Million From Stock Offering To Fund DNA Medicine Development
Management expects the proceeds and existing cash resources to cover operations and capital spending into late fourth quarter 2027.
SEC Filings
Inovio Prices $74.99 Million Offering At $1.05 To Fund VOCERYQ Launch
New common shares represent 34.8% of the post-offering total as Inovio prepares to commercialize its first approved medicine.
Markets
Inovio Stock Plunges 20.69% After Pricing $75 Million Share And Warrant Offering
The DNA-medicine developer priced common shares at $1.05 each and expects the offering to close Monday.
SEC Filings
Inovio Puts Preliminary Cash And Investment Balance At About $48.4 Million
The biotech’s medicines remain in development, and its quarter-end balance is subject to completion of financial closing procedures.
SEC Filings
Inovio Wins FDA Accelerated Approval For Voceryq, Its First Product, After 7 Of 26 Patients Needed No Surgery
The DNA-based RRP therapy cleared on a 12-month complete-response measure, and the FDA wants a confirmatory study protocol by the end of 2026.